Zobrazeno 1 - 10
of 319
pro vyhledávání: '"Athanassios, Argiris"'
Autor:
Angela E. Alnemri, Sruti Tekumalla, Annie E. Moroco, Ioannis Vathiotis, Madalina Tuluc, Stacey Gargano, Tingting Zhan, David M. Cognetti, Joseph M. Curry, Athanassios Argiris, Alban Linnenbach, Andrew P. South, Larry A. Harshyne, Jennifer M. Johnson, Adam J. Luginbuhl
Publikováno v:
Cancer Medicine, Vol 13, Iss 11, Pp n/a-n/a (2024)
Abstract Objectives Certain low‐level immune‐related adverse events (irAEs) have been associated with survival benefits in patients with various solid tumors on immune checkpoint inhibitors (ICIs). We aimed to investigate the association between
Externí odkaz:
https://doaj.org/article/0c9607650bca47c79cde85e796d2846f
Autor:
Nerina Denaro, Lisa Licitra, Marco Merlano, Francesco Perri, Paolo Bossi, Cristina Gurizzan, Federica Perrone, Athanassios Argiris, Loris De Cecco, Stefano Cavalieri, Mara Serena Serafini, Federico Pistore, Deborah Lenoci, Silvana Canevari, Mario Airoldi, Maria Cossu Rocca, Primoz Strojan, Cvetka Grasic Kuhar, Andrea Vingiani, Maria Grazia Ghi, Alessandra Cassano, Giacomo Allegrini
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 1 (2024)
Background Immune checkpoint inhibitors have been approved and currently used in the clinical management of recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients. The reported benefit in clinical trials is variable and h
Externí odkaz:
https://doaj.org/article/b9740be0719d4304a7e872232992bfd0
Autor:
Madalina Tuluc, Jennifer Johnson, Derek Mann, Ubaldo Martinez-Outschoorn, Adam J Luginbuhl, Athanassios Argiris, Ramez Philips, Angela Alnemri, Sruti Tekumalla, Hushan Yang, Alban Linnenbach, Diana Menezes, Voichita Bar-Ad, David Cognetti, Ramakrishna Mitra, Joseph M Curry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/5a43a97980f04c17b24285727b2ad815
Autor:
Madalina Tuluc, Ioannis A Vathiotis, Joseph Curry, Jennifer M Johnson, Ayesha Ali, Larry A Harshyne, Voichita Bar Ad, Rita Axelrod, Emily Lorber, David M Cognetti, Adam J Luginbuhl, Scott Keith, Mỹ G Mahoney, Athanassios Argiris
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 8 (2023)
Background The combination of nivolumab and ipilimumab has been approved for the treatment of multiple solid tumors. This was a phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally
Externí odkaz:
https://doaj.org/article/4fbfb90b2ba3402e9ed28e81355be521
With contributions from internationally recognized experts, Lung Cancer details the current management of lung cancer and reviews new therapies in development for lung cancer, with an emphasis on therapeutic exploitation of the heterogeneous nature o
Autor:
Ramez Philips, Chihun Han, Brian Swendseid, Joseph Curry, Athanassios Argiris, Adam Luginbuhl, Jennifer Johnson
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Despite advances in multimodal treatment for oral cavity squamous cell carcinoma, recurrence rates remain high, providing an opportunity for new therapeutic modalities that may improve oncologic outcomes. Much recent attention has been paid to the mo
Externí odkaz:
https://doaj.org/article/d0d4b976f1e24aafa654e1ba754e8bff
Autor:
Robert I. Haddad, Kevin Harrington, Makoto Tahara, Robert L. Ferris, Maura Gillison, Jerome Fayette, Amaury Daste, Piotr Koralewski, Bogdan Zurawski, Miren Taberna, Nabil F. Saba, Milena Mak, Andrzej Kawecki, Gustavo Girotto, Miguel Angel Alvarez Avitia, Caroline Even, Joaquin Gabriel Reinoso Toledo, Alexander Guminski, Urs Müller-Richter, Naomi Kiyota, Mustimbo Roberts, Tariq Aziz Khan, Karen Miller-Moslin, Li Wei, Athanassios Argiris
Publikováno v:
Journal of Clinical Oncology. 41:2166-2180
PURPOSE CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570 ) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil ≤ six cycles, then cetuximab maintenance) in recurrent/metasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ea41d080266110a8825a284e080af38
https://doi.org/10.1200/jco.22.00332
https://doi.org/10.1200/jco.22.00332
Autor:
Dante J. Merlino, Jennifer M. Johnson, Madalina Tuluc, Stacey Gargano, Robert Stapp, Larry Harshyne, Benjamin E. Leiby, Adam Flanders, Ralph Zinner, Rita Axelrod, Joseph Curry, David M. Cognetti, Kyle Mannion, Young J. Kim, Ulrich Rodeck, Athanassios Argiris, Adam J. Luginbuhl
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
PD-1 blockade represents a promising treatment in patients with head and neck squamous cell carcinoma (HNSCC). We analyzed results of a neoadjuvant randomized window-of-opportunity trial of nivolumab plus/minus tadalafil to investigate whether immuno
Externí odkaz:
https://doaj.org/article/14e95860288848139f6fcb4a69f21798
Autor:
Athanassios Argiris, Lisa Licitra
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Externí odkaz:
https://doaj.org/article/cfe78fcf0699491487b20958c1f6e42d
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
For long, the treatment of locoregionally advanced laryngeal and hypopharyngeal squamous cell cancers (SCC) consisted of either total laryngectomy (TL) or definitive radiotherapy (RT). The development of induction cisplatin plus 5-fluorouracil (PF) a
Externí odkaz:
https://doaj.org/article/61fedd51ad694ece9c164bf304c34bdc